Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has issued an announcement.
Shanghai Fosun Pharmaceutical announced that its board of directors will meet on October 28, 2025, to consider and approve the company’s third-quarter results for the nine months ending September 30, 2025. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its stakeholders and market positioning.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company incorporated in China, operating within the pharmaceutical industry. The company focuses on the development, manufacture, and sale of pharmaceutical products, medical devices, and healthcare services, with a market presence primarily in China.
Average Trading Volume: 11,530,846
Technical Sentiment Signal: Buy
Current Market Cap: HK$81.43B
For an in-depth examination of 2196 stock, go to TipRanks’ Overview page.